Equities

Neuraxis Inc

Neuraxis Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.60
  • Today's Change-0.33 / -11.26%
  • Shares traded28.63k
  • 1 Year change-26.14%
  • Beta--
Data delayed at least 15 minutes, as of Sep 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Neuraxis, Inc. is a medical technology company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It is engaged in advancing science with its IB-Stim therapy, based on its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which was developed internally by the Company. The Company's first product, IB-Stim, is a PENFS system intended to be used in patients 11-18 years of age with functional abdominal pain associated with IBS. The IB-Stim is intended to be used for 120 hours per week for three consecutive weeks, and not to exceed four weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS. Other indications in its pipeline are comprised of functional nausea in children, post-concussion syndrome in children, and cyclic vomiting syndrome in children.

  • Revenue in USD (TTM)2.27m
  • Net income in USD-15.26m
  • Incorporated2022
  • Employees19.00
  • Location
    Neuraxis Inc11611 N. Meridian St, Suite 330CARMEL 46032United StatesUSA
  • Phone+1 (812) 689-0791
  • Fax+1 (845) 818-3588
  • Websitehttp://neuraxis.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
REMSleep Holdings Inc144.88k-1.81m14.41m6.00--25.06--99.46-0.0012-0.00120.00010.00040.081.694.75---99.82-152.40-122.32-317.98-491.08---1,246.94-2,317.521.47-43.580.1207---36.48--12.13--28.26--
Trinity Biotech plc (ADR)58.65m-22.29m14.55m380.00------0.2482-2.74-2.747.23-19.240.70521.693.74154,347.40-26.80-20.30-35.44-29.5434.2839.92-38.01-29.860.8936-2.161.46---9.10-10.1515.41---31.08--
Autonomix Medical Inc-100.00bn-100.00bn15.01m5.00--2.37----------0.2749----------------------------0.1647-------674.99------
LiveCare Inc0.00-2.34m15.26m----6.47-----0.1411-0.14110.000.04630.00-------424.83---550.62-------------8.180.1888-------344.86------
Cutera Inc169.19m-148.97m15.50m430.00------0.0916-7.46-7.468.46-10.730.45722.083.86393,460.50-40.25-22.00-51.64-30.728.1847.63-88.05-27.242.17-31.342.05---15.865.47-97.76--85.87--
Innovative Eyewear Inc1.53m-7.86m15.53m11.00--2.06--10.15-11.01-11.012.054.810.17791.9715.91139,070.90-91.45---96.06---2.46---514.10--12.85--0.00--74.67---17.28------
BioRegenx Inc634.81k-727.95k17.12m10.00--1.01--26.97-0.001-0.0010.00160.01780.0617----63,481.00-7.07---8.46--74.90---114.67--0.1547-8.800.0977---47.25---629.37------
PAVmed Inc3.83m-67.35m17.17m107.00------4.48-8.17-8.170.4595-7.740.0823--29.4535,785.05-155.93-154.56---1,152.82-77.59---1,895.64-8,764.890.5529-8.161.74--550.40--25.76--55.51--
Beyond Air Inc1.78m-58.35m17.78m107.00--1.09--9.97-1.65-1.650.04850.35140.02981.706.8716,663.55-104.22-78.25-137.64-99.91-78.30---3,493.78-6,152.992.42-38.110.4666-----31.57-7.93--152.05--
Spectral AI Inc22.53m-20.24m19.01m78.00------0.8439-1.48-1.481.55-0.24221.68--11.54288,859.00-150.54---954.46--45.12---89.85--0.7066--2.14---28.82---616.14------
Neuraxis Inc2.27m-15.26m20.05m19.00------8.84-3.09-3.090.4039-0.76861.096.6311.80119,318.90-731.17------87.29---672.94--0.2724-19.01-----8.37---163.78------
SeaStar Medical Holding Corp0.00-33.23m20.79m12.00---------21.41-21.410.00-2.140.00----0.00-1,145.80-----------------9.51---------115.19------
Inspira Technologies Oxy BHN Ltd0.00-11.29m23.23m37.00--3.44-----0.9549-0.95490.000.36660.00----0.00-88.60-114.98-108.36-159.56------------0.00------24.64------
IR-Med Inc0.00-3.47m24.05m6.00--66.22-----0.0499-0.04990.000.00510.00----0.00-197.95---273.36--------------0.3019-------3.70------
Orgenesis Inc662.00k-29.02m25.81m146.00------38.99-0.8684-0.86840.02-0.33030.027278.295.384,534.25-122.18---1,312.10---101.06---4,489.28--0.0741-5.85-----98.53-50.94-271.82---17.71--
Data as of Sep 21 2024. Currency figures normalised to Neuraxis Inc's reporting currency: US Dollar USD

Institutional shareholders

2.57%Per cent of shares held by top holders
HolderShares% Held
Next Edge Capital Corp.as of 30 Jun 202465.00k0.95%
The Vanguard Group, Inc.as of 30 Jun 202427.35k0.40%
Stifel Nicolaus & Co., Inc. (Investment Management)as of 30 Jun 202425.71k0.38%
RBC Dominion Securities, Inc. (Investment Management)as of 30 Jun 202415.10k0.22%
Citadel Securities LLCas of 30 Jun 202413.58k0.20%
Parsons Capital Management, Inc.as of 30 Jun 202413.00k0.19%
Geode Capital Management LLCas of 30 Jun 202412.38k0.18%
Tower Research Capital LLCas of 30 Jun 20243.51k0.05%
UBS Securities LLCas of 30 Jun 2024260.000.00%
Bank of America, NA (Private Banking)as of 30 Jun 202418.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.